Rep. Gilbert Ray Cisneros, Jr. Sells Pfizer Inc. (NYSE:PFE) Shares

Posted by Renee Jackson on Jan 15th, 2026

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on January 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on December 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Pfizer Trading Up 1.1%

Pfizer stock traded up $0.28 during trading on Thursday, reaching $25.86. 54,999,060 shares of the company were exchanged, compared to its average volume of 47,469,805. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock’s 50 day simple moving average is $25.31 and its two-hundred day simple moving average is $24.98. The company has a market capitalization of $147.03 billion, a P/E ratio of 15.03 and a beta of 0.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Positive pivotal-trial news: Pfizer reported positive results from Cohort 3 of the BREAKWATER trial for BRAFTOVI + cetuximab + FOLFIRI in BRAF V600E metastatic colorectal cancer — a meaningful oncology readthrough for future sales and label expansion. Why Pfizer Inc. (PFE) is One of the Best Affordable Stocks Under $30
Positive Sentiment: Regulatory push: CEO said Pfizer is pursuing an FDA priority review voucher — could accelerate approvals and shorten time-to-revenue for qualifying assets. Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher
Positive Sentiment: Migraine program progress: Pfizer completed a key China Phase 3 trial for rimegepant and is advancing a CGRP migraine asset with a new bioequivalence study — may support label expansion and China commercial potential. Pfizer Completes Key China Phase 3 Trial for Migraine Drug Rimegepant
Positive Sentiment: Real-world evidence study: Pfizer updated the TOFAst observational study in ulcerative colitis — positive real-world data can support prescribing and payer decisions if results are favorable. Pfizer’s TOFAst Real-World Study in Ulcerative Colitis: What Investors Should Watch
Positive Sentiment: Manufacturing and formulation work: Pfizer initiated bioequivalence studies for a prazosin manufacturing shift and for a CGRP migraine formulation — these moves reduce supply risk and can lower cost/expand access long-term. Pfizer Advances Prazosin Manufacturing Shift With New Bioequivalence Study
Neutral Sentiment: Analyst/investor views: Commentary pieces (Seeking Alpha, TipRanks) pitch Pfizer as a value play given its dividend, pipeline and recent valuation — useful context for longer-term investors but not immediate catalysts. Pfizer: The Most Intriguing Value Play Of 2026
Neutral Sentiment: Institutional ownership: Reports note ~66% institutional ownership — indicates large, stable holders but also potential for outsized moves if institutions rebalance. Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company
Negative Sentiment: Guidance and valuation pressure: Analysts flagged that Pfizer’s market cap fell over $7B in a month after weak 2026 guidance — this continues to weigh on sentiment and caps upside despite positive pipeline news. PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock

Analyst Ratings Changes

Several equities analysts have recently commented on PFE shares. Morgan Stanley decreased their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. UBS Group began coverage on shares of Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. Citigroup initiated coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Finally, HSBC restated a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $27.88.

Check Out Our Latest Stock Report on PFE

Institutional Trading of Pfizer

A number of large investors have recently modified their holdings of PFE. Capital Advisory Group Advisory Services LLC raised its position in Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 388 shares in the last quarter. Citizens National Bank Trust Department raised its holdings in Pfizer by 0.9% in the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 395 shares in the last quarter. Peak Asset Management LLC grew its holdings in Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after acquiring an additional 402 shares in the last quarter. Quest Investment Management LLC increased its position in shares of Pfizer by 1.3% in the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 405 shares during the last quarter. Finally, Community Bank & Trust Waco Texas raised its holdings in shares of Pfizer by 0.6% in the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after purchasing an additional 412 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Pfizer

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.